Fol­low­ing an­oth­er PhII fail­ure, cash-strapped Cerulean chops half its staff

Cerulean ex­ecs end­ed Wednes­day try­ing to con­vince an­a­lysts, large­ly un­suc­cess­ful­ly, that its sec­ond Phase II fail­ure for their lead drug could be con­tained and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.